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Background and purpose: Margin-directed neoadjuvant radiotherapy for borderline-resectable pancreatic
cancer (BRPC) aims to facilitate clear surgical margins. A systematic method was developed for definition
of a boost target volume prior to a formal phase-I study.
Material and methods: Reference structures were defined by two oncologists and one radiologist, target
structures were submitted by eight oncologist investigators and compared using conformity indices.
Resultant risk of duodenal bleed (NTCP) was modelled.
Results: For GTV, reference volume was 2.1 cm3 and investigator mean was 6.03 cm3 (95% CI 3.92–
8.13 cm3), for boost volume 1.1 cm3 and 1.25 cm3 (1.02–1.48 cm3). Mean Dice conformity coefficient
for GTV was 0.47 (0.38–0.56), and for boost volume was significantly higher at 0.61 (0.52–0.70,
p = 0.01). Discordance index (DI) for GTV was 0.65 (0.56–0.75) and for boost volume was significantly
lower at 0.39 (0.28–0.49, p = 0.001). NTCP using reference contours was 2.95%, with mean for investigator
contour plans 3.93% (3.63–4.22%). Correlations were seen between NTCP and GTV volume (p = 0.02) and
NTCP and DI (correlation coefficient 0.83 (0.29–0.97), p = 0.01).
Conclusions: Better conformity with reference was shown for boost volume compared with GTV.
Investigator GTV volumes were larger than reference, had higher DI scores and modelled toxicity risk.
A consistent method of target structure definition for margin-directed pancreatic radiotherapy is
demonstrated.
 2016 Published by Elsevier Ireland Ltd. Radiotherapy and Oncology xxx (2016) xxx–xxxFor patients with a diagnosis of pancreatic cancer surgical
resection is the only chance of achieving long-term disease control,
yet less than 20% will have resectable disease at diagnosis [1]. Even
for resected patients receiving adjuvant chemotherapy, median
survival is only around 24 months [2] suggesting there is signifi-
cant room for improvement by use of optimised multi-modality
therapy including neoadjuvant radiotherapy.
In the largest multi-national adjuvant trial in pancreatic cancer
(involving over 1000 patients) positive surgical margins were seen
in >35% and were associated with poor outcome [2]. Resection
margin status is a strong independent prognostic indicator [3]
and survival for patients with positive margins may be little betterthan for those with unresectable disease [4], though reported rates
of microscopic margin involvement depend greatly on histopatho-
logical techniques [5].
Borderline-resectable pancreatic cancer (BRPC) is a radiological
definition to classify tumours that can be surgically excised but
with likely requirement for vascular reconstruction and particu-
larly high risk of positive resection margins [6]. In UK high-
volume specialist surgical centres the R1 rate for patients undergo-
ing pancreatectomy with vein resection was 62.9% (144/230) and
almost half of these were due to disease at the infiltrated mesen-
teric vessels [7]. The definition of BPRC is controversial with
National Comprehensive Cancer Network (NCCN) criteria being
the most widely accepted.
The management of BPRC is also controversial as there are few
prospective trials and several therapeutic algorithms have been
explored: chemotherapy, radiation and chemoradiation. Current
radiation technology permits exquisite dose painting and theotactic
2 Conformity analysis in pancreatic SBRTpossibility to deliver different radiation doses to adjacent areas in
the target. Delivering a higher dose to the vessels could be there-
fore achieved with the aim to sterilize the margin in the area at
highest risk, and Stereotactic Body Radiation Therapy (SBRT) offers
the opportunity of delivering an ablative dose of RT with short
overall treatment time. Retrospective institutional studies have
demonstrated the feasibility of such an approach with standard
[8,9] or hypofractionation [10,11] but in the case of SBRT a system-
atic method of defining the margin at risk has not been defined.
SPARC (UKCRN ID: 18496) is a CRUK-funded phase 1 dose-
escalation study of pre-operative Margin-Intense Stereotactic
Radiotherapy for patients with BRPC using the NCCN criteria
[12], approved by a National Health Service Research Ethics Com-
mittee. SPARC incorporates a comprehensive radiotherapy quality
assurance programme to ensure consistency in target definition
and radiotherapy delivery. This includes a radiotherapy manual
with atlas, and pre-trial contouring and planning test-cases fol-
lowed by a workshop, both of which have been shown to reduce
variation in target volume definition [13–15]. The radiotherapy
manual specifies that the target structure for the margin-directed
boost should be defined following discussion with the radiologist
and/or Hepato-Pancreato-Biliary (HPB) surgeon to identify the vas-
cular structures that are responsible for the tumour being classified
as borderline resectable according to the NCCN criteria.
We aim to describe a novel method of defining the margin at
risk for radiotherapy planning, testing of the applicability of this
method, and exploration of the implications for Normal Tissue
Complication Probability (NTCP) when SBRT is used.Materials and methods
On an intravenous contrast-enhanced exhale breath-hold CT
(CECT) scan of a suitable test-case of BRPC a set of reference struc-
tures were defined by a team of two expert clinical oncologists and
one radiologist. A contemporaneous 18FDG-PET scan was used to
help interpret CT appearances but the GTV was contoured to define
the extent of gross tumour as evident on the CT scan. The targetFig. 1. Definition of target volumes for SPARC trial. Orange = GTV, Green = VesselConta
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wise manner (see Fig. 1):
(a) The vessel(s) e.g. superior mesenteric artery, superior
mesenteric vein or portal vein should be outlined for their
length that they are in contact with the tumour. This struc-
ture is denoted VesselContact.
(b) This structure is then expanded circumferentially by 3 mm
(i.e. anterior/posterior and laterally but not cranio-
caudally). The resulting structure is denoted Vessel
+ 3 mmC. The GTV is also expanded circumferentially by
3mm to produce GTV + 3mmC.
(c) A Boolean operator is used to define the region that lies in
both Vessel + 3mmC AND GTV + 3mmC, and the resultant
structure is denoted the Boost Volume.
Eight clinical oncologist investigators specialising in pancreatic
cancer were provided with the CT and PET scans, along with radi-
ologist reports, and asked to follow the written instructions for the
delineation of the target structures within the radiotherapy guid-
ance for the SPARC trial protocol. Structure sets were imported into
the Eclipse (version 13, Varian, Palo Alto, CA) radiotherapy treat-
ment planning system (TPS) and descriptive parameters (volume,
centre of mass) and conformity indexes were calculated:
Dice coefficient ¼ 2 ðA \ BÞ
Aþ B
Geographical miss index ¼ B ðA \ BÞ
B
Discordance index ¼ 1 ðA \ BÞ
A
 
where A denotes the investigator structure and B the reference
structure, and A\B denotes intersection of A and B (equivalent to
Boolean operator ‘‘A AND B”).
The trial protocol mandates the use of motion mitigation tech-
niques if motion is greater than 5 mm (for example abdominalct, Red = Boost volume. (For interpretation of the references to color in this figure
onstrate reproducibility of target volumes for Margin-Intense Stereotactic
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Fig. 3. Investigator target structure volumes compared to reference.
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Fig. 4. Mean conformity indices for investigator target structures when assessed
against reference (error bars show 95% confidence interval).
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The CECT is used to confirm the exhale position when reviewing
the 4DCT and the tumour and at risk volumes are contoured on
each phase of the 4DCT to derive the ITV. A 3 mm 3D margin is
then added to create the PTV. On line volumetric image verification
is mandated. An SBRT plan was produced based on the reference
set of target structures, to deliver 35 Gy to the primary tumour
PTV and 50 Gy to the margin at risk (the highest dose level). Treat-
ment is delivered in five daily fractions. This plan was then used to
reproducibly create plans for each set of investigator target struc-
tures, and cumulative dose–volume histogram (DVH) statistics
were extracted describing target coverage and Organ at Risk
(OAR) exposure. The dose–volume constraints for the duodenum
are: D10cc < 25 Gy, D9cc < 15 Gy, D5cc < 25 Gy, D1cc < 33 Gy, Dmax
(0.5cc) < 35 Gy. NTCP for risk of upper gastrointestinal bleed in the
duodenum was modelled using the Lyman-Kutcher Burman model
within the Biological Evaluation Module of the TPS, adopting
parameters derived by Pan et al. (TD50 = 180, m = 0.49, n = 0.12,
a/b ratio = 3) [16]. Shapiro–Wilk testing did not show evidence of
deviation from normality, hence Pearson’s product-moment corre-
lation testing and 2-tailed paired t-tests were performed using
Rstudio [17], and a threshold of p < 0.05 was defined as significant.
Results
Reference and mean investigator volumes for GTV were 2.1 cm3
and 6.03 cm3 (95% CI 3.92–8.13 cm3) respectively, and for boost
volume were 1.1 cm3 and 1.25 cm3 (1.02–1.48 cm3) (Figs. 2 and
3). Mean Dice conformity coefficients for GTV and boost volume
were 0.47 (0.38–0.56) and 0.61 (0.52–0.70), significantly higher
for the boost volume (p = 0.01); mean discordance indices (DI)
were 0.65 (0.56–0.75) and 0.39 (0.28–0.49), significantly lower
for the boost volume (p = 0.001); mean Geographical Miss Indices
(GMI) were 0.17 (0.10–0.23) and 0.33 (0.23–0.43), p = 0.005. Corre-
lation coefficient for GTV volume with DI was 0.93 (0.65–0.99, p =
< 0.001), and for GTV with GMI was 0.06 (0.73–0.68, p = 0.899)
(Fig. 4).
Treatment plans based on the investigator contours were able
to meet the trial planning constraints for target coverage and
OAR avoidance but were associated with an increased risk of NTCP
(duodenal bleed): risk for the plan based on reference target struc-
tures was 2.95%, while mean risk for plans using investigator struc-Fig. 2. Reference (orange = GTV, red = boost volume) and investigator contours (green) of
patient with borderline-resectable pancreatic carcinoma. (For interpretation of the refere
article.)
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correlated with delineated tumour volume (correlation coefficient
0.74, 95% CI 0.15–0.94, p = 0.02) and with discordance index (0.83,
0.29–0.97, p = 0.01) (Fig. 5).Discussion
New techniques in radiotherapy planning, including new target
volume concepts, should be subject to rigorous assessment. Weboost volume (images a and c) and GTV (image b) on contrast-enhanced axial CT of
nces to colour in this figure legend, the reader is referred to the web version of this
onstrate reproducibility of target volumes for Margin-Intense Stereotactic
16), http://dx.doi.org/10.1016/j.radonc.2016.08.001
2 
2.5 
3 
3.5 
4 
4.5 
5 
0.20 0.40 0.60 0.80 1.00 
N
TC
P 
(D
uo
de
nu
m
 b
le
ed
) [
%
]
Discordance Index
Fig. 5. NTCP (risk of duodenal bleed) according to Discordance Index.
4 Conformity analysis in pancreatic SBRTbelieve this is the first analysis of variability in volume delineation
for margin-directed SBRT in pancreatic cancer, in which we have
demonstrated a method that has led to strong inter-user confor-
mity for definition of the boost volume, in a region of complex
anatomy, across multiple centres. No guidelines yet exist for defi-
nition of a margin-directed radiotherapy boost in localised pancre-
atic cancer, but the systematic method for definition of the boost
target structure in the SPARC trial protocol has led to high consis-
tency in clinician target volume definition and in preventing inclu-
sion of more tissue within the target volumes than was intended
by the trial design.
We have shown that the investigator boost volume structures
showed less inter-observer variance in volume compared with
the investigator GTV structures, and investigator GTV volumes
were also larger than the gold standard, while this was not the case
for the boost volume. We have also shown that conformity to ref-
erence, as measured by Dice coefficient, was higher for the boost
volume than for GTV, and Discordance Index (DI) was higher for
GTV, in keeping with ‘over-contouring’. Radiobiological modelling
suggests that radiotherapy plans based on the submitted investiga-
tor contours would have led to increased risk of clinically impor-
tant toxicity (duodenal bleed) and that the risk increased not
only with size of contoured GTV, as might be expected, but partic-
ularly with degree of discordance from reference. Predicted rates of
toxicity remain low, and on a similar scale to those seen in a recent
phase II study of fractionated pancreatic SBRT with gemcitabine
(2% acute and 11% late gradeP 2 upper gastrointestinal toxicity)
[18].
The usefulness of the increased conformality achieved by mod-
ern radiotherapy depends on accurate target definition by the
treating clinician – ‘‘There is little point in worrying about how
to deliver image-guided modulated arc radiation plans if they are
to the wrong target” [19]. Errors in target volume delineation tend
to be larger than other geometric errors in radiotherapy planning,
and also cause a systematic error, not only for a specific patient but
potentially for all patients treated by a given clinician or centre
[20]. In theory the GTV should be a factual entity defined by all
observers in the same way, but despite this significant inter-Table 1
Published reports of margin-directed radiotherapy in pancreatic cancer.
Reference Indication Fractions Tumour dose
Chuong 2013 BRPC or LAPC 5 25–30 Gy
Passoni 2013 LAPC 15 44.25 Gy
Hirata 2015 Resectable PDAC 25 50 Gy
Wang 2015 BRPC or LAPC 28 50.4 Gy
BRPC = Borderline-Resectable Pancreatic Cancer, LAPC = Locally Advanced Pancreatic Can
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and organs at risk [21] and in our study we have observed a large
variation even among a small group of experienced clinicians. In
our study we had intentionally used an ‘expert-defined’ reference
rather than a mathematically-derived consensus contour, and we
feel this has been important in highlighting a systematic pattern
of over-contouring, which would have been obscured by the use
of a consensus definition.
Measures of volume alone cannot assess spatial discrepancy
and thus measures of position should be used, such as through
concordance indices which integrate volumetric and positional dif-
ferences. The Dice coefficient indicates the overall degree of agree-
ment between two contours. Geographical Miss Index (GMI) scores
reflect the amount of the reference contour not included in the
investigator contour, while (DI) indicates the amount of investiga-
tor contour that was not in the reference structure. In our results,
DI scores for GTV were higher than those for boost volume, GMI
scores were lower for GTV than for boost volume while other con-
formity indices were similar for the two structures. Generously
contoured structures may be less likely to exclude any of the refer-
ence structures, and can achieve better GMI scores [22], whereas
the DI is useful to highlight incorrectly large target structures, i.e.
‘‘too much unnecessary volume” [23]. In our data the GTV volume
correlated strongly with DI (p < 0.001), as expected, however GTV
volume did not show a strong negative correlation with GMI, sug-
gesting that generous contouring did not lead to improved tumour
coverage. While the GMI was found to be significantly higher for
the boost volume than for the GTV, the values and range (0.33,
95% CI 0.23–0.43), are similar to those reported for the GTV itself
in another recent investigation of pancreatic tumour definition
(median GMI 0.26, Inter-Quartile Range 0.15–0.40) [24].
Accurate GTV delineation is particularly important in pancreatic
radiotherapy due to the proximity of critical structures, however
the optimal imaging modalities for visualising pancreatic tumours
remain unknown [25]. Pancreatic tumours usually appear hypo-
dense relative to normal pancreas on CECT, but some are isodense
and very difficult to define [26] and it is the junction between
tumour and normal pancreatic tissue where the most variability
has been seen in our results. A diagnostic quality CECT in breath-
hold helps target and normal structure visualisation. Multi-
modality imaging including FDG-PET and multi-parametric MRI
can be used to guide the clinician but the potential effect on out-
comes remains uncertain [25]. In addition pathology correlation
studies suggest that tumour size is underestimated by some imag-
ing modalities [27,28]. The value of direct radiologist support in
radiotherapy planning is increasingly understood [29] however
this does not obviate the requirement for the modern radiation
oncologist to be skilled in multi-modality image interpretation
and have highly detailed anatomical knowledge in order to safely
deliver complex treatments such as described here.
Four prior publications were identified describing the use of
margin-directed radiotherapy in pancreatic cancer (Table 1).
Chuong et al. were first to publish a report of margin-directed
radiotherapy in pancreatic cancer, delivering a simultaneous
integrated boost to a PTV ‘‘encompassed that portion of tumourBoost dose Margin/boost target
30–40 Gy Individualised:- tumour-vessel interface
48–58 Gy Systematic:- infiltrating vessels + 1 cm within GTV
60 Gy Individualised:- roots of coeliac vessels & SMA
56 Gy Systematic:- tumour-vessel interface
cer, PDAC = Pancreatic Ductal AdenoCarcinoma, SMA = Superior Mesenteric Artery.
onstrate reproducibility of target volumes for Margin-Intense Stereotactic
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[30]. The authors describe that they ‘‘tailored the high dose volume
on a case per case basis...the tumor vessel interface (1 cm of vessel
with 1 cm of tumor) was delineated but also modified based on
proximity of critical structures” [10]. A preoperative chemo-
radiotherapy regimen adopted by Hirata et al. also included dose
escalation, targeted at the roots of the coeliac and superior mesen-
teric arteries, being at ‘‘high risk of perineural invasion but difficult
to dissect completely”. The boost target volume was ‘‘personalised
according to guidance from the surgeons or reduced if necessary to
meet duodenal or stomach radiotherapy dose-volume constraints”
[9].
In a prospective phase 1 study in patients with Locally
Advanced Pancreatic Cancer (LAPC), Passoni and colleagues deliv-
ered a simultaneous integrated boost to a target structure encom-
passing the vessels infiltrating the tumour [8]. In this case a
systematic method was used to define the target for the boost:
Infiltrating vessels were contoured and expanded by 1 cm; then
this structure was trimmed to remain within the primary GTV
(in contrast to our approach, in which portions of the boost volume
lie outside the primary GTV). In the most recent publication in this
field the ‘Vessel Boost’ target was defined as the 5 mm of tumour
around the vessel(s) identified that rendered the tumour
borderline-resectable, expanded by a further 5 mm for set-up
error. This methodology is similar to ours, but in the setting of con-
ventionally fractionated treatment, such a technique has not yet
been utilised for SBRT planning [11]. The boost volume we have
described does not have any superior or inferior margin added
prior to ITV and PTV definition. The rationale is to avoid irradiating
part of the vessel that is not in contact with tumour to very high
dose. Part of this vessel will be used for vascular reconstruction
and the long term effect of SBRT on this tissue is unknown.
In conducting radiotherapy clinical trials, consistency of treat-
ment planning and delivery across patients and recruiting centres
is required not only for sound conclusions to be drawn regarding
the treatment intervention but also because radiotherapy that is
not delivered per-protocol is associated with worse patient out-
comes [31]. In a study of chemoradiotherapy for locally-advanced
pancreatic cancer, protocol deviations such as unnecessarily large
target volumes correlated with risk of significant toxicity [32]
while in a large study of adjuvant chemoradiotherapy after resec-
tion of pancreatic adenocarcinoma, failure to adhere to the radio-
therapy protocol was associated with decreased overall survival
[33]. Therefore, it is recommended that radiotherapy trials are sup-
ported by a prospective and comprehensive quality assurance pro-
gramme [20]. We have shown that pancreatic GTV delineation
remains difficult, which reinforces the importance of pre-
treatment central review of target structures to ensure consistency
and quality across recruiting centres.Conclusions
We have demonstrated a robust systematic method for delin-
eation of the boost volume for margin-intense pancreatic SBRT,
and with the use of a detailed protocol and atlas within a clinical
trial setting this has led to less inter-user variability and greater
conformity with a reference contour than was observed for defini-
tion of the primary tumour GTV. We have also shown variability in
GTV definition with implications for modelled toxicity risk, high-
lighting the difficulties in pancreatic tumour delineation and rein-
forcing the importance of continuing on-trial RTQA.Conflict of interest statement
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